The Investsmart website has an interview on it from only a few...

The Investsmart website has an interview on it from only a few days back (17th April) that is definitely worth a listen or read. Alan Kohler from the Eureka Report is speaking with Megan Baldwin. The extensive and comprehensive interview runs for over 28 mins. The transcript is lot quicker to read! Alan Kohler acknowledges in the first instance that they don't cover many biotechs because they are highly speculative usually but Opthea is interesting.
Megan does provide some interesting insights as to how the company is progressing. Only a few patients in the AMD phase IIB trial are yet to complete their 6 month dosing and they are on schedule for an October readout for this trial. The DME IIA is not yet fully recruited but they are hopeful of a readout by end of 2019.
There is a lot of talk in the interview about the different potential business opportunities OPT-302 could create for the company pending successful trials. Sounds like there has been a lot of talk going on behind the scenes with pharmaceutical companies involved in this space.